Suchergebnisse - "Azad, Arun A"

PubPharm (118)

1

Precision medicine for prostate cancer : An international perspective

enthalten in: Urologic oncology | 2024

von Hamid, A. | Sweeney, C. | Hovens, C. | +2

2

Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP) : A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

enthalten in: European urology oncology | 2024

von Gafita, A. | Martin, A. | Emmett, L. | +10

3

Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy) : A Single-centre, Single-arm, Phase 1/2 Study

enthalten in: European urology | 2024

von Eapen, R. | Buteau, J. | Jackson, P. | +21

4

TALAPRO-3 clinical trial protocol : phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

enthalten in: Future oncology (London, England) | 2024

von Agarwal, N. | Saad, F. | Azad, A. | +8

5

PCPro : a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer

enthalten in: Prostate cancer and prostatic diseases | 2024

von Scheinberg, T. | Lin, H. | Fitzpatrick, M. | +10

6

Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer

enthalten in: Radiation oncology (London, England) | 2024

von Ali, M. | Koo, K. | Chang, D. | +12

7

Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer

enthalten in: Radiation oncology | 2024

von Ali, M. | Koo, K. | Chang, D. | +12

8

Role of FDG PET/CT in Management of Patients with Prostate Cancer

enthalten in: Seminars in nuclear medicine | 2024

von Sutherland, D. | Azad, A. | Murphy, D. | +3

9

Publisher Correction : First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

ErratumFor: Nat Med. 2024 Jan;30(1):257-264. - PMID 38049622

10

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP) : secondary outcomes of a randomised, open-label, phase 2 trial

enthalten in: The Lancet. Oncology | 2024

von Hofman, M. | Emmett, L. | Sandhu, S. | +60

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]